A practical reference on Angiotensin IV analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-08 and is reviewed periodically as new material appears.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
=== South Pacific === Australia: BCG vaccination was used between the 1950s and mid-1980s. BCG has not been part of routine vaccination since the mid-1980s. New Zealand: BCG Immunisation was first introduced for 13-year-olds in 1948. Vaccination was phased out from 1963 to 1990.
=== Alternative medicine === Though there is no evidence for the safety or efficacy of using curcumin as a therapy, some alternative medicine practitioners give it intravenously, supposedly as a treatment for numerous diseases. In 2017, two serious cases of adverse events were reported from curcumin or turmeric products—one severe allergic reaction and one death—that were caused by administration of a curcumin-polyethylene glycol (PEG40) emulsion product by a naturopath. One treatment caused anaphylaxis leading to death.
==== Blue ==== Prussian blue, or blue, a coloring used in the treatment of radiation, cesium, and thallium poisoning, can turn the feces blue. Substantial consumption of products containing blue food dye, such as blue curaçao or grape soda, can have the same effect.
== Synthesis == Clicked peptide polymers are prepared by the azide-alkyne Huisgen cycloaddition also called the click reaction; which is commonly used in bioconjugation reactions to link molecules together with a stable triazole bridge. Peptide based polymers are produced from a cycloaddition variant of step-growth polymerization. The monomers used in this polymerization are oligopeptides with terminal azide and terminal alkyne groups
Sources: en.wikipedia.org
Some competition came from the newly independent United States, which began to compete in Guangzhou, selling Turkish opium in the 1820s. Portuguese traders also brought opium from the independent Malwa states of western India, although by 1820, the British were able to restrict this trade by charging "pass duty" on the opium when it was forced to pass through Bombay to reach an entrepot. Despite drastic penalties and continued prohibition of opium until 1860, opium smuggling rose steadily from 200 chests per year under the Yongzheng Emperor to 1,000 under the Qianlong Emperor, 4,000 under the Jiaqing Emperor, and 30,000 under the Daoguang Emperor. This illegal sale of opium, which has been called "the most long continued and systematic international crime of modern times", became one of the world's most valuable single commodity trades, and between 1814 and 1850, sucked out 11 percent of China's money supply. In response to the ever-growing number of Chinese people becoming addicted to opium, the Qing Daoguang Emperor took strong action to halt the smuggling of opium, including the seizure of cargo. In 1838, the Chinese Commissioner Lin Zexu destroyed 20,000 chests of opium (approximately 2,660,000 pounds) in Guangzhou in a river. Given that a chest of opium was worth nearly US$1,000 in 1800, this was a substantial economic loss. The British queen Victoria, not willing to replace the cheap opium with costly silver, began the First Opium War in 1840, the British winning Hong Kong and trade concessions in the first of a series of Unequal Treaties..
== Pharmacology == The pharmacodynamic profile of deupsilocin, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin. As with psilocin, deupsilocin is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals. However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration. In humans, deupsilocin has been reported to have 2.2-fold higher peak levels and 3.5-fold higher area-under-the-curve (AUC) levels than psilocybin at equivalent doses. It is said to have a rapid onset of less than 15 minutes and a duration of 4 to 6 hours.
Honey use and production has a long and varied history, with its beginnings in prehistoric times. Several cave paintings in Cuevas de la Araña in Spain depict humans foraging for honey at least 8,000 years ago. While Apis mellifera is an Old World insect, large-scale meliponiculture of New World stingless bees has been practiced by Mayans since pre-Columbian times.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.